Our 2015 approach to invasive pulmonary aspergillosis

Mycoses

Volumn 58, Issue 6, 2015, Pages 375-382

  Liss, B ^a,b   Vehreschild, J J ^a,b   Bangard, C ^a   Maintz, D ^a   Frank, K ^a   Gronke S ^a   Michels, G ^a   Hamprecht, A ^a   Wisplinghoff, H ^a   Markiefka, B ^a   Hekmat, K ^a   Vehreschild, M J G T ^a,b   Cornely, O A ^a,b,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Aspergillosis; Caspofungin; Liposomal amphotericin B; Mould pneumonia; Neutropaenia; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; GALACTOMANNAN; MANNAN; TRIAZOLE DERIVATIVE;

CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DECISION TREE; FEVER; HUMAN; LUNG ASPERGILLOSIS; LUNG INFILTRATE; LUNG SURGERY; MUCORMYCOSIS; NONHUMAN; PERCUTANEOUS BIOPSY; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY; ASPERGILLUS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOPROPHYLAXIS; FEVER OF UNKNOWN ORIGIN; FRANCE; INVASIVE PULMONARY ASPERGILLOSIS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; UNIVERSITY HOSPITAL;

ANTIFUNGAL AGENTS; ASPERGILLUS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOPREVENTION; FEVER OF UNKNOWN ORIGIN; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MANNANS; MICROBIAL SENSITIVITY TESTS; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES;

EID: 84929465460     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12319     Document Type: Review

References (89)

1. Bohme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
2. Lagrou K, Buchheidt D, Richardson M et al. Diagnostic Group 2014 ESCMID Aspergillus GuidelineESCMID. Barcelona, Spain: EFSIG, 2014.
3. Cornely OA, Cuenca-Estrella M, Meis JF, Ullmann AJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin Microbiol Infect 2014; 20(Suppl 3): 1-4.
4. Tacke D, Buchheidt D, Karthaus M et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Ann Hematol 2014; 93: 1449-56.
5. Tsitsikas DA, Morin A, Araf S et al. Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis. Med Mycol 2012; 50: 538-42.
6. Bodro M, Sabe N, Gomila A et al. Risk factors, clinical characteristics, and outcomes of invasive fungal infections in solid organ transplant recipients. Transplant Proc 2012; 44: 2682-5.
7. Sganga G, Bianco G, Frongillo F, Lirosi MC, Nure E, Agnes S. Fungal infections after liver transplantation: incidence and outcome. Transplant Proc 2014; 46: 2314-8.
8. Bitar D, Lortholary O, Le Strat Y et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 2014; 20: 1149-55.
9. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
10. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
11. Murray CJ, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-223.
12. Menzin J, Meyers JL, Friedman M et al. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control 2011; 39: e15-20.
13. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
14. Guinea J, Torres-Narbona M, Gijon P et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2010; 16: 870-7.
15. Patterson JE, Zidouh A, Miniter P, Andriole VT, Patterson TF. Hospital epidemiologic surveillance for invasive aspergillosis: patient demographics and the utility of antigen detection. Infect Control Hosp Epidemiol 1997; 18: 104-8.
16. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005; 9: R191-9.
17. Cunha C, Aversa F, Lacerda JF et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med 2014; 370: 421-32.
18. Cunha C, Aversa F, Romani L, Carvalho A. Human genetic susceptibility to invasive aspergillosis. PLoS Pathog 2013; 9: e1003434.
19. von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62: 341-7.
20. Gerson SL, Talbot GH, Lusk E, Hurwitz S, Strom BL, Cassileth PA. Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis. J Clin Oncol 1985; 3: 1109-16.
21. Denning DW, Marinus A, Cohen J et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome. J Infect 1998; 37: 173-80.
22. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
23. Cornely OA, Maertens J, Bresnik M et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2011; 54: e449-55.
24. Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-47.
25. Cornely O, Vehreschild JJ, Vehreschild MJ. http://innere1.uk-koeln.de/pdf/studien/behandlungspfade/Behandlungspfad_Febrile-Neutropenie_10.2014.pdf, 2014.
26. Heimann SM, Cornely OA, Vehreschild MJ et al. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis. Mycoses 2014; 57: 90-7.
27. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-10.
28. Ruhnke M, Bohme A, Buchheidt D et al. Diagnosis of invasive fungal infections in hematology and oncology-guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 2012; 23: 823-33.
29. Schwartz S, Thiel E. Clinical presentation of invasive aspergillosis. Mycoses 1997; 40(Suppl 2): 21-4.
30. Maschmeyer G, Beinert T, Buchheidt D et al. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82(Suppl 2): S118-26.
31. Tacke D, Koehler P, Markiefka B, Cornely OA. Our 2014 approach to mucormycosis. Mycoses 2014; 57: 519-24.
32. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41: 60-6.
33. Vehreschild JJ, Ruping MJ, Wisplinghoff H et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010; 65: 1466-71.
34. Koehler P, Tacke D, Cornely OA. Our 2014 approach to candidaemia. Mycoses 2014; 57: 581-3.
35. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88: 115-9.
36. Cornely OA, Ullmann AJ. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther 2011; 89: 351-2.
37. Cornely OA, Helfgott D, Langston A et al. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother 2012; 56: 2652-8.
38. Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56: 5503-10.
39. Kohl V, Muller C, Cornely OA et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010; 54: 207-12.
40. Vehreschild JJ, Muller C, Farowski F et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol 2012; 68: 987-95.
41. Duarte RF, Lopez-Jimenez J, Cornely OA et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 2014; 58: 5758-65.
42. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
43. Link H, Bohme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82(Suppl 2): S105-17.
44. Vehreschild MJ, Vehreschild JJ, Hubel K et al. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Oncol 2013; 24: 1189-202.
45. Vehreschild MJ, Meissner AM, Cornely OA et al. Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. Haematologica 2011; 96: 1855-60.
46. Koehler P, Tacke D, Cornely OA. Aspergillosis of bones and joints - a review from 2002 until today. Mycoses 2014; 57: 323-35.
47. Clancy CJ, Jaber RA, Leather HL et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45: 1759-65.
48. Kim SW, Rhee CK, Kang HS et al. Diagnostic value of bronchoscopy in patients with hematologic malignancy and pulmonary infiltrates. Ann Hematol 2015; 94: 153-9.
49. Meersseman W, Lagrou K, Maertens J et al. Galactomannan in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 2008; 177: 27-34.
50. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-9.
51. Ruping MJ, Vehreschild JJ, Groll A et al. Current issues in the clinical management of invasive aspergillosis-the AGIHO, DMykG, OGMM and PEG web-based survey and expert consensus conference 2009. Mycoses 2011; 54: e557-68.
52. Cornely OA, Arikan-Akdagli S, Dannaoui E et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20(Suppl 3): 5-26.
53. Lass-Florl C, Resch G, Nachbaur D et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45: e101-4.
54. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
55. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
56. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
57. Cornely OA, Bohme A, Schmitt-Hoffmann A, Ullmann AJ. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother 2015; Apr 59(4): 2078-85.
58. Ruping MJ, Muller C, Vehreschild JJ et al. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. Mycoses 2011; 54: 230-3.
59. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
60. Cornely OA, Maertens J, Bresnik M, Ullmann AJ, Ebrahimi R, Herbrecht R. Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B. J Antimicrob Chemother 2010; 65: 114-7.
61. Cornely OA, Vehreschild JJ, Vehreschild MJGT et al. Phase II dose escalation study of caspofungin for invasive aspergillosis. Antimicrob Agents Chemother 2011; 55: 5798-803.
62. Brodoefel H, Vogel M, Hebart H et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. AJR Am J Roentgenol 2006; 187: 404-13.
63. Lim C, Seo JB, Park SY et al. Analysis of initial and follow-up CT findings in patients with invasive pulmonary aspergillosis after solid organ transplantation. Clin Radiol 2012; 67: 1179-86.
64. Kim K, Lee MH, Kim J et al. Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Am J Hematol 2002; 71: 75-9.
65. Matt P, Bernet F, Habicht J et al. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 2004; 126: 1783-8.
66. Nosari A, Ravini M, Cairoli R et al. Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant 2007; 39: 631-5.
67. Mousset S, Buchheidt D, Heinz W et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014; 93: 13-32.
68. Groll AH, Castagnola E, Cesaro S et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014; 15: e327-40.
69. Spiess B, Seifarth W, Merker N et al. Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients. Antimicrob Agents Chemother 2012; 56: 3905-10.
70. Hoenigl M, Prattes J, Spiess B et al. Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2014; 52: 2039-45.
71. Willinger B, Lackner M, Lass-Florl C et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis in solid organ transplant patients: a semiprospective multicenter study. Transplantation 2014; 98: 898-902.
72. Pazos C, Ponton J, Del Palacio A. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299-305.
73. Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR. Reactivity of (1->3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006; 50: 3450-3.
74. Pruller F, Wagner J, Raggam RB et al. Automation of serum (1->3)-beta-D-glucan testing allows reliable and rapid discrimination of patients with and without candidemia. Med Mycol 2014; 52: 455-61.
75. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47: 846-54.
76. Hammarstrom H, Kondori N, Friman V, Wenneras C. How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors. Eur J Clin Microbiol Infect Dis 2015.
77. Potenza L, Vallerini D, Barozzi P et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood 2011; 118: 5416-9.
78. Potenza L, Barozzi P, Vallerini D et al. Diagnosis of invasive aspergillosis by tracking Aspergillus-specific T cells in hematologic patients with pulmonary infiltrates. Leukemia 2007; 21: 578-81.
79. Bacher P, Kniemeyer O, Schonbrunn A et al. Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. Mucosal Immunol 2014; 7: 916-28.
80. Bacher P, Steinbach A, Kniemeyer O et al. Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection. Am J Respir Crit Care Med 2015; 191: 348-52.
81. Hamprecht A, Buchheidt D, Vehreschild JJ et al. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill 2012; 17: 20262.
82. Spiess B, Postina P, Reinwald M et al. Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013. PLoS ONE 2014; 9: e103113.
83. Steinmann J, Hamprecht A, Vehreschild MJ et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 2015.
84. Ananda-Rajah MR, Grigg A, Downey MT et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 2012; 97: 459-63.
85. Duarte RF, Sanchez-Ortega I, Cuesta I et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis 2014; 59: 1696-702.
86. Lerolle N, Raffoux E, Socie G et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect 2014; 20: O952-9.
87. Winston DJ, Bartoni K, Territo MC, Schiller GJ. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17: 507-15.
88. Marr KA, Schlamm HT, Herbrecht R et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162: 81-9.
89. Cornely OA, Meems L, Herbrecht R, Viscoli C, vanAmsterdam RG, Ruhnke M. Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. Mycoses 2015; 58: 58-64.